Insider · CIK 0002049888
Charles Calderaro III
Files at RNA (Avidity Biosciences, Inc.). First filing Jan 9, 2026, latest Jan 9, 2026.
In brief
Charles Calderaro III files SEC Form 4 as officer at RNA (Avidity Biosciences, Inc.). Since Jan 9, 2026, Charles Calderaro III has reported 0 open-market buys worth $0 and 1 open-market sell worth $269k, the latest filed on Jan 9, 2026.
A track record needs three past buys with six months of prices behind them; Charles Calderaro III has 0, so none is measured yet.
The newest scored trade: sold $269k of RNA on Jan 7, 2026, filed Jan 9, 2026, scored 23 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $269k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Avidity Biosciences, Inc. | $269k 3,727 shares | -7% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -98,547 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Feb 27, 2026 |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -3,727 | $72.23 | $269k | 49,797 | Jan 9, 2026 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +23,250 | $0.00 | $0 | 63,250 | Dec 19, 2025 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | FTax withholding Common Stock | -9,726 | $71.87 | $699k | 53,524 | Dec 19, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 40,000 | Jan 8, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jan 8, 2025 |
Questions about Charles Calderaro III
Answered from the filings on this page, as of the latest one.
Is Charles Calderaro III buying or selling?
In the last 12 months Charles Calderaro III reported 0 open-market buys worth $0 and 1 open-market sell worth $269k on SEC Form 4; the latest was sold $269k of RNA on Jan 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Charles Calderaro III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles Calderaro III has 0.
Where does Charles Calderaro III file Form 4?
Charles Calderaro III has filed Form 4 at RNA (Avidity Biosciences, Inc.) as Chief Technical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.